George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...